Navigation Links
ARIUS announces fourth quarter and year-end fiscal 2007 financial results
Date:1/29/2008

TORONTO, Jan. 29 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced its financial and operational results for the fourth quarter and fiscal year, ended November 30, 2007.

"Fiscal 2007 was a critical year in our development, highlighted by the significant advancement we made with the pre-IND programs for our lead drug candidates, our CD44 Cancer Stem Cell Program, our Trop-2 Signal Transduction Program, our CD59 Complement Inhibitor Program and our CD9 Cancer Stem Cell Program. The majority of our programs target cancer stem cells, an area that cancer researchers are particularly excited about as cancer stem cells have been implicated as the key cells responsible for the growth and spread of cancer," said Dr. David Young, President and CEO. "Building on this momentum, fiscal 2008 will be a pivotal year for us as we transition from a pre-clinical to a clinical company with the mission of moving one or more of our lead products into human clinical trials."

Program Updates:

CD44 Cancer Stem Cell Program

- Announced positive findings demonstrating no dose-limiting toxic

effects of ARIUS' lead therapeutic, ARH460-16-2, at doses up to

95 mg/kg in a dose-ranging pilot toxicology study in a non-human

primate model.

- Achieved significant and potent tumor growth inhibitory activity in

in vivo animal models of breast, prostate, liver, and AML cancers.

- Engaged the manufacturer Avid Bioservices to produce ARIUS' lead

anti-CD44 MAb under Current Good Manufacturing Practices ("cGMP") for

human clinical trials. Cell line producing the humanized anti-CD44

antibody was successfully transferred to Avid.

- Presented key data at AACR, ASCO, ASCO's Breast Cancer Symposium,

and AACR-EORTC.

- Met with FDA to discuss plans (15,032,405) -

-------------------------------------------------------------------------

Deficit, end of period (32,533,633) (21,476,594) (32,533,633)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Loss per share -

basic and diluted (0.25) (0.18)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Weighted average common shares

outstanding 44,750,964 35,751,822

-------------------------------------------------------------------------

-------------------------------------------------------------------------

ARIUS RESEARCH INC.

(A DEVELOPMENT STAGE COMPANY)

STATEMENTS OF CASH FLOWS

-------------------------------------------------------------------------

Period from

incorporation

on August 11,

1999 to

Years ended November 30, November 30,

2007 2006 2007

$ $ $

-------------------------------------------------------------------------

Cash provided by (used in):

Operating activities:

Loss for the period (11,057,039) (6,444,189) (32,533,633)

Items not involving cash:

Amortization of:

Facilities and equipment 389,713 215,793 1,278,871

Deferred costs - 55,055 55,055

Leasehold inducements (41,486) (5,852) (56,153)

Loss/(Gain) on disposal

of equipment - 31,518 23,532

Write-off of leasehold

improvements - - 86,349

Leasehold inducement - 71,095 89,148

Non-cash stock-based

compensation 845,202 593,327 1,630,601

Accretion of convertible

debentures - 396,511 429,905

Loss on extinguishment

of debt - 782,143 782,143

Services received for

common shares - - 400,024

Write-off of investment - - 20,000

Interest expense paid in

common shares - 140,032 140,032

Change in non-cash operating

working capital items 2,881,338 1,016,936 5,063,547

-----------------------------------------------------------------------

(6,982,272) (3,147,631) (22,590,579)

Financing activities:

Issue of shares, warrants

and units, net of issuance

costs - 24,853,112 38,281,778

Issuance of convertible

bridge loan, net - 2,126,619 2,196,619

Repayment of convertible

bridge loan, including costs - (2,338,886) (2,408,886)

Exercise of compensation

warrants - - 8,581

Draw of bank line of credit - - 655,000

Repayment of bank line of

credit - (85,000) (655,000)

Bridge loan - - 300,000

Repayment of bridge loan - (300,000) (300,000)

Repayment of capital lease

and equipment financing

obligations (29,630) (91,019) (290,431)

-----------------------------------------------------------------------

(29,630) 24,164,826 37,787,661

Investing activities:

Purchase of short-term

investments (27,015,587) (16,135,490) (43,151,077)

Maturity of short-term

investments 36,325,887 - 36,325,887

Leasehold inducements - 243,780 243,780

Long-term investment - - (20,000)

Acquisition of facilities

and equipment (740,098) (1,201,387) (2,969,293)

Disposal of equipment - - 8,986

-----------------------------------------------------------------------

8,570,202 (17,093,097) (9,561,717)

Increase (decrease) in cash

and cash equivalents 1,558,300 3,924,098 5,635,365

Cash and cash equivalents,

beginning of period 4,077,065 152,967 -

-------------------------------------------------------------------------

Cash and cash equivalents,

end of period 5,635,365 4,077,065 5,635,365

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Forward-Looking Statements

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in ARIUS' Annual Report, forthcoming news releases and other filings with Canadian securities regulatory authorities available at http://www.sedar.com. Forward-looking statements are based on our current expectations and ARIUS is not obligated to update such information to reflect later events or developments.

for the upcoming IND submission.

- Prepared to file a Phase I IND application and begin human clinical

trials for the CD44 Cancer Stem Cell program in 2008.

Trop-2 Signal Transduction Program

- Announced positive findings demonstrating a significant anti-tumor

effect of the lead anti-Trop-2 antibody in animal models of human

pancreatic cancer, inhibiting tumor growth by up to 100 percent.

- Discovered that ARIUS' Trop-2 antibody inhibits a key growth

regulatory pathway in cancer cells.

- Trop-2 therapeutic antibody program was selected for presentation and

press conference at the AACR-NCI-EORTC 2007 International Conference

on Molecular Targets and Cancer Therapeutics. The abstract was one of

only 12 selected from more than 900 abstracts for presentation.

- Engaged the manufacturer Laureate Pharma Inc. for the cGMP

manufacture of humanized AR47A6.4.2 for Phase 1 clinical supply. Cell

line producing the humanized anti-Trop-2 antibody was successfully

transferred to Laureate.

- Preparing to complete the dose ranging toxicology studies in the

first quarter of 2008, followed by a pre-IND meeting with the FDA in

the third quarter of 2008, and the filing of a Phase I IND

application in late 2008.

CD59 Complement Inhibitor Program

- Announced positive findings demonstrating highly potent tumor

regression in animal models of breast cancer at doses as low as

0.2 mg/kg.

- Selected to discuss results of the CD59 therapeutic antibody program

at the AACR-NCI-EORTC 2007 International Conference on Molecular

Targets and Cancer Therapeutics press conference.

- Cell line producing humanized CD59 antibody was generated

successfully; humanized mAb retains binding characteristics and

potent in vivo activity.

- Preparing to perform preclinical toxicology studies in 2008 in

preparation for filing a Phase I IND application.

CD9 Cancer Stem Cell Program

- CD9 is more highly expressed in leukemia stems cells than normal

stem cells.

- Presented positive findings demonstrating the ability of the lead

anti-CD9 antibody to kill cancer stem cells in an in vivo model using

cells from human leukemia patients.

- Demonstrated ability to kill cancer stem cells while potentially

leaving normal cells alone.

CD63 Antibody Program

- Licensed to Genentech, Inc. in March 2006, the CD63 program continues

to advance in preclinical studies in a variety of cancer indications

as part of a program to move the lead antibody towards the clinic.

Takeda Collaboration

- Discovered and delivered novel antibodies to Takeda under the terms

of the research collaboration agreement, ARIUS has successfully met

its obligations to date and has received all scheduled research

payments from Takeda.

Additional Product Updates

- Currently, ARIUS has antibody programs targeting the MCSP antigen and

37LRP, in addition to several other undisclosed programs.

- Furthered lead optimization for antibodies covering additional novel

targets generated using ARIUS' proprietary FunctionFIRST(TM)

technology.

Other Highlights:

- Granted eight US patents for antibodies and one European patent to

date, and currently have 18 issued or allowed patents covering its

antibody programs and discovery platform and over 185 patents pending

worldwide.

- Promoted Susan Hahn, PhD to the position of Vice President of

Development.

- Appointed Mr. James Rae and Mr. Joseph Zakrzewski to its Board of

Directors and also appointed Mr. Carl Gordon as non-executive Chair

of the Board of Directors.

Financial Results:

All amounts are in Canadian dollars unless otherwise indicated.

For the year ended November 30, 2007, the Company recorded a net loss of $11,057,039 compared to a net loss of $6,444,189 for the year ended November 30, 2006. The increase in net loss was the result of higher research and development, general administrative and foreign exchange expenses and lower revenues, partially offset by lower interest expense and the absence of a loss on extinguishment of debt. For the three-month period ended November 30, 2007, the Company recorded a net loss of $2,952,338 compared to a net loss of $3,623,727 for the three-month period ended November 30, 2006. This decrease in net loss for the three-month period is primarily the result of lower research and development, general and administrative and interest expenses and the 2006 one time loss on extinguishment of debt of $782,143 relating to the repayment of the convertible bridge loan, partially offset by higher foreign exchange losses and income tax expense.

Revenue decreased to $1,144,094 for the year ended November 30, 2007, compared to $2,847,761 for the year ended November 30, 2006. The decrease during the year ended November 30, 2007, was primarily the result of the recognition of licensing fee revenue from Genentech in the fiscal 2006 period and a decrease in financial contributions from the National Research Council's Industrial Research Assistance Program, partially offset by the recognition of product and research contract revenue from the Takeda collaboration and the recognition of unearned revenue for PDL BioPharma Inc. in the fiscal 2007 period. For the three-month period ended November 30, 2007, the Company's revenue increased to $298,120 compared to $179,751 for the three-month period ended November 30, 2006. The increase was primarily the result of the recognition of product and research contract revenue from the Takeda collaboration.

Interest income decreased to $679,457 for the year ended November 30, 2007, compared to $726,308 for the same period in fiscal 2006. For the three-month period ended November 30, 2007, the Company's interest income decreased to $142,329 compared to $329,342 for the same period in fiscal 2006. The decrease in interest income is the result of lower average cash and investment balances.

Research and development costs amounted to $8,606,344 for the year ended November 30, 2007, compared to $5,688,029 for the same period in fiscal 2006. For the three-month period ended November 30, 2007, the Company's research and development costs amounted to $2,144,353 compared to $2,512,366 for the same period in fiscal 2006. For the year, this increase is primarily the result of increased product development activity, including process development and scale-up, as the Company prepares several of its programs for the clinic as well as an increase in staffing levels and stock option remuneration expense. For the three month period, the decrease in research and development costs is primarily the result of decreased stock option remuneration expense and a decrease in legal expense for patents, offset by an increase in staffing levels.

General and administrative expenses increased to $3,257,430 for the year ended November 30, 2007, compared to $2,833,802 for the same period in fiscal 2006. For the three-month period ended November 30, 2007, the Company's general and administrative expenses decreased to $691,910 compared to $806,589 for the same period in fiscal 2006. The increase for the year is the result of increased head count, stock option remuneration expense, and severance costs, partially offset by decreased consulting and legal costs. The decrease for the three month period is the result of a decrease in stock option remuneration expense, professional fees and salaries, partially offset by an increase in consulting and directors fees.

As at November 30, 2007, the Company's cash and cash equivalents, short-term investments and working capital position were $5,635,365, $6,825,190 and $9,088,712 respectively, compared with November 30, 2006 balances of $4,077,065, $16,135,490 and $20,222,321, respectively. The Company believes that it has adequate financial resources for anticipated expenditures until the fourth quarter of fiscal 2008.

Conference Call

ARIUS will host a conference call today (Tuesday January 29, 2008 at 8:00 a.m. ET) to discuss its fourth quarter and year-end fiscal 2007 results. To access the conference call by telephone, dial 416-644-3414 or 1-800-731-6941. Please connect approximately five minutes prior to the beginning of the call to ensure participation. A live audio webcast of the conference call will be available at http://www.ariusmabs.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above website for 365 days.

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit http://www.ariusmabs.com

Financial Information to follow:

ARIUS RESEARCH INC.

(A DEVELOPMENT STAGE COMPANY)

BALANCE SHEETS

As of November 30, 2007 and 2006

-------------------------------------------------------------------------

2007 2006

$ $

-------------------------------------------------------------------------

Assets

Current assets:

Cash and cash equivalents 5,635,365 4,077,065

Short-term investments 6,825,190 16,135,490

Receivables 230,126 716,727

Refundable tax credits 400,000 400,000

Prepaid expenses 387,674 340,695

-----------------------------------------------------------------------

13,478,355 21,669,977

Facilities and equipment, net 1,889,921 1,539,536

-------------------------------------------------------------------------

15,368,276 23,209,513

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Liabilities and Shareholders' Equity

Current liabilities:

Accounts payable and accrued liabilities 2,034,972 1,211,528

Accrued loss on embedded foreign exchange

derivative 296,064 -

Current portion of leasehold inducements 41,484 41,486

Current portion of capital lease obligation 25,710 29,630

Current portion of deferred revenue and

contract advances 1,991,413 165,012

-----------------------------------------------------------------------

4,389,643 1,447,656

Leasehold inducements 235,291 276,775

Capital lease obligation 2,224 27,934

Deferred revenue and contract advances 1,758,898 2,263,091

Shareholders' equity:

Share capital:

Common shares 28,644,454 28,644,454

Warrants 9,603,644 9,603,644

Compensation warrants 912,377 912,377

Contributed surplus 2,355,378 1,510,176

Deficit (32,533,633) (21,476,594)

-----------------------------------------------------------------------

8,982,220 19,194,057

-------------------------------------------------------------------------

15,368,276 23,209,513

-------------------------------------------------------------------------

-------------------------------------------------------------------------

ARIUS RESEARCH INC.

(A DEVELOPMENT STAGE COMPANY)

STATEMENTS OF OPERATIONS, COMPREHENSIVE LOSS AND DEFICIT

-------------------------------------------------------------------------

Period from

incorporation

on August 11,

1999 to

Years ended November 30, November 30,

2007 2006 2007

$ $ $

-------------------------------------------------------------------------

Revenue:

Research contract 746,780 - 746,780

Product 158,942 - 158,942

Licensing fees 165,012 2,678,087 3,284,703

Research grant payments 73,360 169,674 273,663

-----------------------------------------------------------------------

1,144,094 2,847,761 4,464,088

Expenses:

Research and development,

net of tax credits of

$200,000 (2005 - $200,000) 8,606,344 5,688,029 25,398,579

General and administrative 3,257,430 2,833,802 10,997,811

Foreign exchange loss (gain) 764,695 (38,626) 710,836

Interest expense 2,874 752,910 904,397

-----------------------------------------------------------------------

12,631,343 9,236,115 38,011,623

-----------------------------------------------------------------------

Loss before the undernoted (11,487,249) (6,388,354) (33,547,535)

Interest income 679,457 726,308 2,045,292

Loss on extinguishment of debt - (782,143) (782,143)

-------------------------------------------------------------------------

Loss before income taxes (10,807,792) (6,444,189) (32,284,386)

Income taxes:

Current (249,247) - (249,247)

-------------------------------------------------------------------------

Loss and comprehensive loss

for the period (11,057,039) (6,444,189) (32,533,633)

Deficit, beginning of period: (21,476,594)
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
2. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
3. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
4. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
5. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
6. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
7. ARIUS to present at Chinese Global Financial Forum
8. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
9. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
10. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
11. China Bionanometer Industries Corporation Announces Record Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... 02, 2016 , ... StarNet Communications Corp, ( http://www.starnet.com/ ) a leading publisher ... Remote Desktop modules to its flagship X-Win32 PC X server. The new modules ... the user’s PC over encrypted SSH. , Traditionally, users of PC X servers deploy ...
(Date:4/29/2016)... Italy (PRWEB) , ... April 30, 2016 , ... The ... extraordinary textile design, the bioLogic team explored how bacterial properties can be applied to ... of using Natto bacteria, which move in response to humidity change. The team harvested ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... in spinal surgical procedures, today announced the completion of a significant transaction and ... current and future customers and partners. Kohlberg & Company, L.L.C. (“Kohlberg”), a ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... to transform technology into a viable company, CereScan’s CEO, John Kelley, joined other ... a recognized leader and mentor in the Denver area business community, shared his ...
Breaking Biology Technology:
(Date:3/15/2016)... Yissum Research Development Company of the Hebrew University ... University, announced today the formation of Neteera Technologies ... biological indicators. Neteera Technologies has completed its first round ... Neteera,s ... from sweat ducts, enables reliable and speedy biometric identification, ...
(Date:3/10/2016)... -- --> --> ... Access Management Market by Component (Provisioning, Directory Services, Password ... Size, by Deployment, by Vertical, and by Region - ... is estimated to grow from USD 7.20 Billion in ... Compound Annual Growth Rate (CAGR) of 12.2% during the ...
(Date:3/8/2016)... 2016   Valencell , the leading innovator ... has secured $11M in Series D financing. The ... venture fund being launched by UAE-based financial services ... investors TDF Ventures and WSJ Joshua Fund. Valencell ... triple-digit growth and accelerate its pioneering innovation in ...
Breaking Biology News(10 mins):